Therapy of carcinoma with lysodren (o,p'-DDD): Experience in therapeutical management by monitoring of o,p'-DDD blood levels;Therapie des nebennierenrindenkarzinoms mit lysodren (o,p'-DDD). Erfahrungen mit der therapiesteuerung durch monitoring der serumspiegel von o,p'-DDD

Medizinische Klinik

Volumn 96, Issue 7, 2001, Pages 371-377

  Heilmann, Peter ^a   Wagner, Philipp ^a   Nawroth, Peter P ^a   Ziegler, Reinhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adrenocortical carcinoma; Drug monitoring; O,p' DDD

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX INSUFFICIENCY; ARTICLE; CANCER RECURRENCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; TISSUE NECROSIS; TREATMENT PLANNING;

EID: 0035878781     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002218     Document Type: Article

References (25)

1. Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian national registry for adrenal cortical carcinoma
2. Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma
3. Adrenocortical tumors: Recent advances in basic concepts and clinical management
4. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study
5. Eastern Cooperative Oncology Group study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma
6. Is there a role for low dose of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
7. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
8. Determination of 18β-glycyrrhetinic acid in human serum using the fully automated ALCA-system
9. Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery
10. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients
11. Extensive personal experience: Adrenocortical tumors
12. Surgical management, DNA content and patient survival in adrenal cortical carcinoma
13. Clinical features of adrenocortical carcinoma, prognostic factors and the effect of mitotane therapy
14. Cancer of the adrenal cortex: The natural history, prognosis and treatment in a study of fifty-five cases
15. Estimation of o,p'-DDD in plasma by gas liquid chromatography
16. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDE or TDE)
17. Automated liquid chromatographic determination of the 20-dihydro isomers of cortisol and cortisone in human urine
18. New "on-line" sample pretreatment procedure for routine liquid-chromatographic assay of low-concentration compounds in body fluids illustrated by triamcinolone assay
19. Adrenocortical carcinoma
20. Urinary oestriol-16-glucuronide determined by "on-Line"-liquid chromatography
21. The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic simplications of serum level monitoring
22. O,p'-DDD (Mitotane) levels in plasma and tissues during chemotherapy and at autopsy
23. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
24. Adrenal cortical carcinoma
25. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature